Insider Transactions in Q1 2022 at Nuvectis Pharma, Inc. (NVCT)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+0.14%
|
$28,000
$7.05 P/Share
|
|
Mar 17
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
7,000
+0.25%
|
$49,000
$7.63 P/Share
|
|
Feb 14
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
8,000
+0.28%
|
$40,000
$5.88 P/Share
|
|
Feb 10
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
8,500
+0.3%
|
$51,000
$6.34 P/Share
|
|
Feb 07
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.36%
|
$120,000
$6.09 P/Share
|
|
Feb 07
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
846
+0.07%
|
$2,538
$3.47 P/Share
|
|
Feb 07
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
800
+0.07%
|
$2,400
$3.88 P/Share
|
|
Feb 04
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
212,500
+3.6%
|
$850,000
$4.45 P/Share
|
|
Feb 04
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
2,100
+0.18%
|
$6,300
$3.38 P/Share
|
|
Feb 04
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
3,800
+0.32%
|
$11,400
$3.35 P/Share
|